局部晚期-话题@MedSci

#局部晚期#

176篇内容 | 3367人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2232517, encodeId=4b97223251e5f, content=<a href='/topic/show?id=146246308d1' target=_blank style='color:#2F92EE;'>#宫颈癌#</a> <a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=打破25年僵局！《柳叶刀》：死亡风险降低40%，宫颈癌治疗再迎突破, objectType=article, longId=848135, objectId=e7be84813566, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230607/1686120557420_5579292.jpg, objectUrl=/article/show_article.do?id=e7be84813566, replyNumber=0, likeNumber=52, createdTime=2024-10-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e7be84813566, moduleTitle=打破25年僵局！《柳叶刀》：死亡风险降低40%，宫颈癌治疗再迎突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7be84813566)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2216503, encodeId=8b892216503af, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=9f4919e766f' target=_blank style='color:#2F92EE;'>#三维适形放疗#</a> <a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=解决争议，影响近1/3常见肺癌患者！安全延长生存期，精准放疗技术怎么选？, objectType=article, longId=835775, objectId=e1d0835e75c1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240713/1720882427885_5579292.png, objectUrl=/article/show_article.do?id=e1d0835e75c1, replyNumber=0, likeNumber=117, createdTime=2024-07-23, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e1d0835e75c1, moduleTitle=解决争议，影响近1/3常见肺癌患者！安全延长生存期，精准放疗技术怎么选？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1d0835e75c1)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1650867, encodeId=0457165086eb8, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=PLoS One :局部晚期基底细胞癌的评估和治疗, objectType=article, longId=738673, objectId=365ce3867325, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=365ce3867325, replyNumber=0, likeNumber=117, createdTime=2023-02-28, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=365ce3867325, moduleTitle=PLoS One :局部晚期基底细胞癌的评估和治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=365ce3867325)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650863, encodeId=74f8165086313, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=局部晚期头颈部癌症也可治愈！微创手术、质子、免疫、光免疫疗法提高治愈可能！, objectType=article, longId=735536, objectId=90a4e3553666, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90a4e3553666, replyNumber=0, likeNumber=86, createdTime=2022-09-17, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90a4e3553666, moduleTitle=局部晚期头颈部癌症也可治愈！微创手术、质子、免疫、光免疫疗法提高治愈可能！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90a4e3553666)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650860, encodeId=43f7165086018, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Clin Cancer Res：局部晚期头颈部鳞状细胞癌的新辅助化疗+免疫治疗, objectType=article, longId=731133, objectId=8c55e311334c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c55e311334c, replyNumber=0, likeNumber=97, createdTime=2023-02-23, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c55e311334c, moduleTitle=Clin Cancer Res：局部晚期头颈部鳞状细胞癌的新辅助化疗+免疫治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c55e311334c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650868, encodeId=9840165086800, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Rhizen Pharmaceuticals AG宣布即将在ESMO 2022上展示其临床阶段的资产数据；Tenalisib治疗局部晚期/转移性乳腺癌和RP12146治疗多种实体瘤, objectType=article, longId=739183, objectId=460ce39183f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=460ce39183f7, replyNumber=0, likeNumber=0, createdTime=2022-10-07, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=460ce39183f7, moduleTitle=Rhizen Pharmaceuticals AG宣布即将在ESMO 2022上展示其临床阶段的资产数据；Tenalisib治疗局部晚期/转移性乳腺癌和RP12146治疗多种实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=460ce39183f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650855, encodeId=a9e716508558c, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Rhizen Pharmaceuticals AG在2022年欧洲肿瘤内科学会乳腺癌会议上公布一项进行中的Tenalisib (RP6530)治疗局部晚期或转移性乳腺癌患者II期研究的中期积极数据, objectType=article, longId=726291, objectId=eddae262914c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eddae262914c, replyNumber=0, likeNumber=92, createdTime=2023-01-07, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eddae262914c, moduleTitle=Rhizen Pharmaceuticals AG在2022年欧洲肿瘤内科学会乳腺癌会议上公布一项进行中的Tenalisib (RP6530)治疗局部晚期或转移性乳腺癌患者II期研究的中期积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eddae262914c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650853, encodeId=ea87165085343, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=NICE推荐Bavncio (avelumab)治疗局部晚期转移性尿路上皮癌 (UC), objectType=article, longId=724472, objectId=bbc0e244722a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bbc0e244722a, replyNumber=0, likeNumber=79, createdTime=2022-07-07, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bbc0e244722a, moduleTitle=NICE推荐Bavncio (avelumab)治疗局部晚期转移性尿路上皮癌 (UC), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bbc0e244722a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650856, encodeId=0820165085653, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=ADV：Sonidegib治疗局部晚期基底细胞癌回顾性研究, objectType=article, longId=728083, objectId=7358e280834f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7358e280834f, replyNumber=0, likeNumber=0, createdTime=2023-02-07, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7358e280834f, moduleTitle=ADV：Sonidegib治疗局部晚期基底细胞癌回顾性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7358e280834f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650851, encodeId=22c4165085100, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=BMC Cancer：局部晚期非小细胞肺癌（LA-NSCLC）放化疗后durvalumab治疗可改善患者的预后, objectType=article, longId=723788, objectId=3020e23788de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3020e23788de, replyNumber=0, likeNumber=79, createdTime=2022-09-14, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3020e23788de, moduleTitle=BMC Cancer：局部晚期非小细胞肺癌（LA-NSCLC）放化疗后durvalumab治疗可改善患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3020e23788de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650852, encodeId=2bf3165085289, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=AACR重磅：局部晚期或转移性胃/GEJ癌患者使用抗TTX-030联合化学免疫疗法的一线治疗的安全性有效性评估, objectType=article, longId=723989, objectId=0551e2398931, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0551e2398931, replyNumber=0, likeNumber=117, createdTime=2023-02-06, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0551e2398931, moduleTitle=AACR重磅：局部晚期或转移性胃/GEJ癌患者使用抗TTX-030联合化学免疫疗法的一线治疗的安全性有效性评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0551e2398931)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650864, encodeId=73ba1650864f8, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Lancet Oncol：新辅助放化疗加用Galunisertib可提高局部晚期直肠癌的完全缓解率, objectType=article, longId=735465, objectId=7ce2e3546529, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ce2e3546529, replyNumber=0, likeNumber=152, createdTime=2023-07-23, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ce2e3546529, moduleTitle=Lancet Oncol：新辅助放化疗加用Galunisertib可提高局部晚期直肠癌的完全缓解率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ce2e3546529)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650844, encodeId=9b9e1650844e9, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=Clin Cancer Res：帕博利珠单抗新辅助和辅助治疗可切除局部晚期头颈部鳞状细胞癌患者的疗效, objectType=article, longId=300287, objectId=836930028e24, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=836930028e24, replyNumber=0, likeNumber=102, createdTime=2023-02-12, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=836930028e24, moduleTitle=Clin Cancer Res：帕博利珠单抗新辅助和辅助治疗可切除局部晚期头颈部鳞状细胞癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=836930028e24)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650847, encodeId=f780165084e38, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=ESMO：化疗联合纳武利尤单抗对局部晚期可切除NSCLC治疗，42个月OS率达87.3%（NADIM研究）, objectType=article, longId=301725, objectId=d251301e254c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d251301e254c, replyNumber=0, likeNumber=88, createdTime=2022-03-31, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d251301e254c, moduleTitle=ESMO：化疗联合纳武利尤单抗对局部晚期可切除NSCLC治疗，42个月OS率达87.3%（NADIM研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d251301e254c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650865, encodeId=4fc816508659e, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=【今晚直播】局部晚期肺癌基于分子分期和分子分型的“个体化”MDT治疗策略, objectType=article, longId=736155, objectId=6d55e3615518, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d55e3615518, replyNumber=0, likeNumber=60, createdTime=2023-06-22, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d55e3615518, moduleTitle=【今晚直播】局部晚期肺癌基于分子分期和分子分型的“个体化”MDT治疗策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d55e3615518)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650861, encodeId=093d1650861ab, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=CCR：突破局部晚期治疗瓶颈！武汉协和医院MDT头颈部肿瘤成果刷新国际记录，晚期肿瘤治疗有效率达96%, objectType=article, longId=732387, objectId=f8fee323876e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8fee323876e, replyNumber=0, likeNumber=101, createdTime=2022-12-03, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8fee323876e, moduleTitle=CCR：突破局部晚期治疗瓶颈！武汉协和医院MDT头颈部肿瘤成果刷新国际记录，晚期肿瘤治疗有效率达96%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8fee323876e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650866, encodeId=79ab165086658, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=JAMA Oncol：卡巴他赛在转移性/局部晚期去分化脂肪肉瘤中的活性, objectType=article, longId=738663, objectId=5cfee38663b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cfee38663b9, replyNumber=0, likeNumber=103, createdTime=2023-06-20, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cfee38663b9, moduleTitle=JAMA Oncol：卡巴他赛在转移性/局部晚期去分化脂肪肉瘤中的活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5cfee38663b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650835, encodeId=b571165083527, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=JAMA Oncol：阿帕替尼 vs安慰剂治疗局部晚期或转移性、放射性碘难治分化型甲状腺癌患者的疗效: 随机临床研究REALITY, objectType=article, longId=292261, objectId=67d0292261ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67d0292261ff, replyNumber=0, likeNumber=99, createdTime=2022-10-20, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67d0292261ff, moduleTitle=JAMA Oncol：阿帕替尼 vs安慰剂治疗局部晚期或转移性、放射性碘难治分化型甲状腺癌患者的疗效: 随机临床研究REALITY, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67d0292261ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650854, encodeId=32081650854c9, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=BMC Med：阿帕替尼+奥沙利铂+卡培他滨新辅助治疗局部晚期胃癌/胃食管交界处癌, objectType=article, longId=726038, objectId=a34fe2603805, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a34fe2603805, replyNumber=0, likeNumber=110, createdTime=2022-12-06, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a34fe2603805, moduleTitle=BMC Med：阿帕替尼+奥沙利铂+卡培他滨新辅助治疗局部晚期胃癌/胃食管交界处癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a34fe2603805)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1650857, encodeId=e347165085e19, content=<a href='/topic/show?id=ffae4e614b6' target=_blank style='color:#2F92EE;'>#局部晚期#</a>, objectTitle=NEJM Evid：durvalumab联合标准化疗治疗局部晚期或转移性胆道癌, objectType=article, longId=729496, objectId=5ebee29496b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ebee29496b6, replyNumber=0, likeNumber=79, createdTime=2022-12-12, rootId=0, userName=yhy100208, userId=901d24099859, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ebee29496b6, moduleTitle=NEJM Evid：durvalumab联合标准化疗治疗局部晚期或转移性胆道癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ebee29496b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

局部晚期

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#宫颈癌# #局部晚期#

打破25年僵局！《柳叶刀》：死亡风险降低40%，宫颈癌治疗再迎突破

2024-10-22发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #三维适形放疗# #局部晚期#

解决争议，影响近1/3常见肺癌患者！安全延长生存期，精准放疗技术怎么选？

2024-07-23发表于上海

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

PLoS One :局部晚期基底细胞癌的评估和治疗

2023-02-28

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

局部晚期头颈部癌症也可治愈！微创手术、质子、免疫、光免疫疗法提高治愈可能！

2022-09-17

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Clin Cancer Res：局部晚期头颈部鳞状细胞癌的新辅助化疗+免疫治疗

2023-02-23

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Rhizen Pharmaceuticals AG宣布即将在ESMO 2022上展示其临床阶段的资产数据；Tenalisib治疗局部晚期/转移性乳腺癌和RP12146治疗多种实体瘤

2022-10-07

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Rhizen Pharmaceuticals AG在2022年欧洲肿瘤内科学会乳腺癌会议上公布一项进行中的Tenalisib (RP6530)治疗局部晚期或转移性乳腺癌患者II期研究的中期积极数据

2023-01-07

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

NICE推荐Bavncio (avelumab)治疗局部晚期转移性尿路上皮癌 (UC)

2022-07-07

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

ADV：Sonidegib治疗局部晚期基底细胞癌回顾性研究

2023-02-07

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

BMC Cancer：局部晚期非小细胞肺癌（LA-NSCLC）放化疗后durvalumab治疗可改善患者的预后

2022-09-14

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

AACR重磅：局部晚期或转移性胃/GEJ癌患者使用抗TTX-030联合化学免疫疗法的一线治疗的安全性有效性评估

2023-02-06

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Lancet Oncol：新辅助放化疗加用Galunisertib可提高局部晚期直肠癌的完全缓解率

2023-07-23

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

Clin Cancer Res：帕博利珠单抗新辅助和辅助治疗可切除局部晚期头颈部鳞状细胞癌患者的疗效

2023-02-12

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

ESMO：化疗联合纳武利尤单抗对局部晚期可切除NSCLC治疗，42个月OS率达87.3%（NADIM研究）

2022-03-31

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

【今晚直播】局部晚期肺癌基于分子分期和分子分型的“个体化”MDT治疗策略

2023-06-22

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

CCR：突破局部晚期治疗瓶颈！武汉协和医院MDT头颈部肿瘤成果刷新国际记录，晚期肿瘤治疗有效率达96%

2022-12-03

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

JAMA Oncol：卡巴他赛在转移性/局部晚期去分化脂肪肉瘤中的活性

2023-06-20

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

JAMA Oncol：阿帕替尼 vs安慰剂治疗局部晚期或转移性、放射性碘难治分化型甲状腺癌患者的疗效: 随机临床研究REALITY

2022-10-20

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

BMC Med：阿帕替尼+奥沙利铂+卡培他滨新辅助治疗局部晚期胃癌/胃食管交界处癌

2022-12-06

yhy100208 (审核中...)

前往app查看评论内容

#局部晚期#

NEJM Evid：durvalumab联合标准化疗治疗局部晚期或转移性胆道癌

2022-12-12

科室
- - 订阅+
  - 更多科室
工具
服务